富马酸伏诺拉生(Vonoprazan Fumarate) - 药物靶点：H+/K+ ATPase_在研适应症：非糜烂性胃食管反流病，糜烂性食管炎，胃灼热_专利_临床

概要

基本信息

药物类型

小分子化药

别名

VONOPION、Vonoprazan、Vonoprazan Fumarate

+ [24]

靶点

H+/K+ ATPase

作用方式

阻滞剂

作用机制

H+/K+ ATPase阻滞剂(钾离子转运ATP酶复合体阻滞剂)

治疗领域

感染消化系统疾病口颌疾病+ [4]

在研适应症

非糜烂性胃食管反流病糜烂性食管炎胃灼热+ [7]

非在研适应症

消化不良非糜烂性反流病

原研机构

Takeda Pharmaceutical Co., Ltd.

在研机构

Takeda Pharmaceutical Co., Ltd.

宜昌东阳光长江药业股份有限公司Takeda Pharmaceuticals Korea Co., Ltd.

+ [3]

非在研机构

Hanlim Pharm Co., Ltd.

浙江尖峰药业有限公司

Kokando Co., Ltd.

+ [1]

权益机构

Takeda Pharmaceutical Co., Ltd.

Phathom Pharmaceuticals, Inc.

Lupin Ltd

+ [3]

最高研发阶段批准上市

首次获批日期

日本 (2014-12-26),

十二指肠溃疡反流性食管炎幽门螺杆菌感染+ [1]

最高研发阶段(中国)批准上市

特殊审评-

登录后查看时间轴

结构/序列

分子式C21H20FN3O6S

InChIKeyROGSHYHKHPCCJW-WLHGVMLRSA-N

CAS号881681-01-2

关联

569

项与富马酸伏诺拉生相关的临床试验

NCT07752407

/ Not yet recruiting临床3期

A Phase 3, Randomized, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of Vonoprazan 10 mg Compared to Placebo for Relief of Episodic Heartburn in Subjects With Symptomatic Non-Erosive Gastroesophageal Reflux Disease Through 24 Weeks

The main objective is to assess the efficacy of vonoprazan (10 mg as needed) compared to placebo (as needed) in relief of episodic heartburn at 2 hours that is sustained for 24 hours over 12 weeks of treatment in participants with non-erosive gastroesophageal reflux disease (GERD).

开始日期2026-09-25

申办/合作机构

Phathom Pharmaceuticals, Inc.

NCT07757919

/ Not yet recruiting临床4期IIT

Efficacy and Safety of 14-Day Vonoprazan-Minocycline Dual Therapy for Helicobacter Pylori Eradication: A Multicenter, Non-Inferiority Randomized Controlled Trial

Investigators will enroll treatment-naïve H. pylori-positive patients according to the inclusion and exclusion criteria in the trial. After obtaining written informed consent, investigators will open envelopes labeled with corresponding subject numbers in the order of subject enrollment to determine group allocation. Subjects will receive interventions according to their assigned regimens: the 14-day vonoprazan-amoxicillin dual therapy regimen, the 14-day vonoprazan-tetracycline dual therapy regimen, or the 14-day vonoprazan-minocycline dual therapy regimen.
Meanwhile, investigators will complete the case report forms (CRFs) to record subjects' basic demographic information and risk factors for eradication failure. Subjects will be asked to fill out patient diaries to document medication administration and adverse reactions. After trial initiation, investigators will follow up with subjects via telephone or WeChat and collect patient diaries, summarize medication status and adverse reactions during treatment, and assess subject compliance.
Six weeks after the end of treatment, subjects will undergo a repeat ¹³C-urea breath test. Investigators will record treatment outcomes and re-examination results, finalize the case report forms, and upload photographs of original examination documents.
After all subjects finish the trial, the eradication rate, incidence of adverse events and subject compliance in each group will be calculated. Statistical analyses will be performed to compare demographic characteristics and risk factors between patients with eradication success and eradication failure. The findings will provide evidence for the selection of H. pylori eradication regimens.

开始日期2026-09-01

申办/合作机构

山东大学齐鲁医院

NCT07772700

/ Not yet recruitingN/AIIT

Potassium-competitive Acid Blocker Versus Double Dose Proton Pump Inhibitors in High High-risk Peptic Ulcer Bleeding: A Randomized Controlled Trial

This randomized clinical trial will enroll patients at National Cheng Kung University Hospital who have upper gastrointestinal ulcer bleeding, have undergone endoscopic hemostasis, and have a Rockall score of 6 or higher.
A total of 108 patients will be enrolled and randomly assigned to two groups: Standard-treatment group: 54 patients, Experimental group: 54 patients.
Both groups will receive standard endoscopic hemostasis and 72 hours of intravenous PPI therapy. Thereafter, patients in the standard-treatment group will receive double-dose PPI therapy, whereas patients in the experimental group will receive a P-CAB per day. All patients will be followed for 28 days to assess the occurrence of rebleeding.

开始日期2026-09-01

申办/合作机构

国立成功大学医学院附属医院

100 项与富马酸伏诺拉生相关的临床结果

登录后查看更多信息

100 项与富马酸伏诺拉生相关的转化医学

登录后查看更多信息

100 项与富马酸伏诺拉生相关的专利（医药）

登录后查看更多信息

881

项与富马酸伏诺拉生相关的文献（医药）

2026-12-01·JOURNAL OF MEMBRANE BIOLOGY

Protonation of Key Acidic Residues Reveals Binding Features of PCABs to Gastric H, K-ATPase

Article

作者: Zerbetto De Palma, Gerardo ; Cerf, Nicole T ; Montes, Mónica R

The group of inhibitors known as Potassium Competitive Acid Blockers (PCABs) has become one of the main topics of current research into reducing gastric H,K-ATPase activity. The design of novel PCABs relies on structure-based drug design strategies that integrate structural data with molecular dynamics simulations. A key aspect in conventional molecular dynamics simulations is the assignment of residue charge states, since the local physicochemical environment influences the pKa of amino acids. This computational work investigates the impact of the protonation state of key residues on the interactions between PCABs and the gastric H,K-ATPase. The study focusses on Glu343, Glu795, and Glu820, from the cation binding cavity, and vonoprazan and tegoprazan; two chemically unrelated PCABs. The results show how protonation states generate changes in interactions, especially with the charged group of inhibitors. Simulations in which Glu343 or Glu795 were protonated showed that the charged secondary amine of vonoprazan could rotate freely, favoring hydrogen bonding with some of the glutamic residues deep within the pocket. In contrast, the positive charge of tegoprazan is located in the benzimidazole ring, a rigid and bulky structure, which moves away from the center of the cavity when Glu343 or Glu795 are protonated. The inspection of the ionization states of amino acids reveals the conformational flexibility of the protonated group of PCABs as pivotal for binding affinity and highlights the importance of considering the protonation state of protein residues before performing any conventional molecular dynamics simulations for drug design.

2026-09-01·JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES

Stability-indicating RP-HPLC–DAD method for aspirin and vonoprazan using analytical quality by design and comprehensive greenness assessment

Article

作者: Goli, Sravya ; Alegete, Pallavi ; Ajmeera, Meghana

This fixed-dose combination is intended for patients requiring long-term aspirin-based antiplatelet therapy who are at increased risk of gastrointestinal complications, with vonoprazan providing gastroprotection through potent acid suppression. A robust RP-HPLC method was developed through Failure Mode Effects Analysis (FMEA) risk assessment and face-centered central composite design (FCCD) optimization. Chromatographic separation on a Zorbax SB-C18 column (250 × 4.6 mm, 5 μm) using isocratic elution with water-acetonitrile-formic acid (75:25:0.05, v/v/v) at 0.8 mL/min and 30 °C achieved baseline resolution within 8.5 min, with quantification of both analytes performed at a single wavelength of 280 nm. Quantification was performed at a single detection wavelength of 280 nm, while peak purity was evaluated using DAD spectral data over 220-350 nm. Peak purity was confirmed by DAD spectral analysis, with purity angle values lower than purity threshold values for both Aspirin (ASP) and vonoprazan fumarate (VPZ) under all tested conditions. The method demonstrated stability-indicating specificity through ICH Q1A(R2)-compliant forced degradation studies, while LC-MS/MS characterization showed that VPZ underwent hydroxylation (m/z 378.1754), N-oxidation (m/z 346.0993), demethylation (m/z 315.0568), and pyridine cleavage (m/z 301.1419), among the identified degradation products. Environmental sustainability was comprehensively evaluated using complementary assessment tools, namely the GAPI pictogram, AGREE (0.79), Eco-Scale (90/100), ChlorTox (0.43 mg CHCl₃-eq), BAGI (82.5), and CACI (85.0), confirming favorable environmental compatibility and practical feasibility for routine quality-control application.

2026-07-04·IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY

Pharmacovigilance analysis of vonoprazan: a disproportionality analysis based on the FDA adverse event reporting system database

Article

作者: Zhang, Wenchao ; Liu, Boyi ; Chen, Danna ; Han, Ao

OBJECTIVE:

Vonoprazan is a novel potassium-competitive acid blocker whose expanding clinical application necessitates comprehensive evaluation of its real-world safety profile.

METHODS:

Utilizing the FAERS database, this study collected adverse event (AE) data associated with vonoprazan therapy from the first quarter of 2013 to the second quarter of 2025. Disproportionality analysis was performed using both the Reporting Odds Ratio (ROR) and Bayesian Confidence Propagation Neural Network (BCPNN) methods. Furthermore, a Weibull distribution model was employed to characterize the temporal risk patterns of the identified adverse events.

RESULTS:

A total of 1315 reports of adverse events (AEs) associated with vonoprazan were identified in this study. Analysis revealed several potential safety signals, including: gastric cancer (ROR = 9.26, 95%CI: 5.48-15.65; IC = 3.21, IC025 = 1.83), dysgeusia (ROR = 2.31, 95%CI: 1.24-4.29; IC = 1.2, IC025 = 0.17), and esophageal candidiasis (ROR = 36.36, 95%CI: 18.16-72.82; IC = 5.18, IC025 = 1.92).

CONCLUSION:

Although signal detection analysis based on the FAERS database cannot establish causality, our study suggests that vonoprazan treatment may significantly increase the risks of nausea, hypertension, and gastric cancer, highlighting the need for enhanced monitoring in clinical practice. Future research should validate these signals through prospective trials and mechanistic studies to optimize the risk-benefit profile of vonoprazan therapy.

760

项与富马酸伏诺拉生相关的新闻（医药）

2026-08-22

·同花顺

天士力上半年创新管线持续兑现

1、天士力公司2026年上半年在控费政策和市场竞争下，坚持研发创新，加码创新布局，执行“创新中药与先进治疗药物”双轮驱动战略。 2、公司在心血管及代谢、神经/精神、消化三大核心领域有33项在研创新药，其中3项处于NDA/Pre NDA阶段，18项处于临床II、III期阶段。 3、公司提升研发效率和创新能力，加速重磅产品上市进程，在创新中药领域，1.1类中药创新药枣仁宁心滴丸获批上市，TCM2219申报NDA，TCM0117完成Pre NDA沟通交流会议。 4、在先进治疗药物领域，公司积极布局细胞与基因治疗(CGT)、小核酸等先进治疗药物赛道，3项CGT药物I期临床研究入组中，1项小核酸药物处于临床前研究。 5、公司以技术平台为底座，以高端人才为引擎，驱动研发能力从“经验驱动”向“平台驱动”跃升。 6、上半年公司实现重要项目里程碑9项，除注册申报进展外，还有其他里程碑进展，包括TCM1802-01启动III期临床，CMI1203启动IIb期临床等。 2026年上半年，国内医药行业在控费政策、市场竞争交织下持续调整，但优质企业却更多关注长期发展，坚持研发创新力度不减。天士力（600535）最新公布的半年报显示，公司依托稳健经营底盘持续加码创新布局，坚定执行“创新中药与先进治疗药物”双轮驱动战略，一批在研项目接连抵达关键临床与注册节点，创新转化效能持续释放，创新管线迎来集中兑现期。研发效率快速提升公告称，公司聚焦心血管及代谢、神经/精神、消化三大核心领域，拥有在研创新药（002173）33项，其中处于NDA/Pre NDA阶段3项，处于临床II、III期阶段18项。报告期内，公司以提升研发效率和创新能力为核心举措，稳步推进各项创新工作。在研发效率提升方面，公司聚焦创新中药与先进治疗药物两大板块，加速重磅产品上市进程。在创新中药领域，公司通过推进“现代中药创制全国重点实验室”建设，加快创新中药研发进程，报告期内1.1类中药创新药（002173）枣仁宁心滴丸获批上市，TCM2219申报NDA，TCM0117完成Pre NDA沟通交流会议，共18项创新中药处于临床II、III期及NDA阶段；在先进治疗药物领域，公司积极布局细胞与基因治疗(CGT)、小核酸等先进治疗药物赛道，3项CGT药物I期临床研究入组中，1项小核酸药物处于临床前研究。创新能力向“平台驱动”跃升在创新能力提升方面，公司以技术平台为底座，以高端人才为引擎，驱动研发能力从“经验驱动”向“平台驱动”跃升。在创新中药领域，重点攻关微滴丸制剂技术，已启动4项探索并突破2项共性技术；主导制定的中医药2项ISO国际标准正式发布，通过标准领先增强研发创新能力；在先进治疗药物领域，CGT赛道重点攻关“生物资源库、基因编辑平台与CMC开发平台”的“一库两平台”建设。报告期内，与北京市神经外科研究所等密切合作，联合申报获批“神经肿瘤细胞治疗北京市重点实验室”；在小核酸药物领域深化产学研合作，加速构建覆盖“序列设计-固相合成-先进递送”的全链条研发技术平台。为强化高端人才领航，公司持续优化研发人才结构，提升创新人才比例，重点引进CGT药物研发、小核酸药物研发、临床医学等前沿领域核心技术人才，不断夯实研发创新能力。临床申报高效推进公司提升研发效率，注册申报的关键里程碑高效达成。上半年公司创新药（002173）处于申报生产阶段项目4项，截至目前枣仁宁心滴丸获批上市，CMI1808申报生产已提交发补资料，TCM2219已提交NDA，TCM0117完成Pre NDA交流。此外，仿制药米诺地尔搽剂、波生坦分散片、富马酸伏诺拉生片获得药品注册批件，盐酸伐昔洛韦片通过一致性评价。上半年公司实现重要项目里程碑9项，除前述注册申报进展外，另有其他里程碑进展：TCM1802-01启动III期临床，CMI1203启动IIb期临床，BIO2601本年度新立项并已获批IND，CMI2402申报IND，TCM2105申报IND，TCM2601完成立项。对标年度计划，6项进度超前，包括TCM0013、TCM1207均提前完成III期全部病例入组，B2065I期临床已进入第三剂量组入组、TCM2008提前获得CDE的EOP2意见等。(

临床3期上市批准申请上市临床1期临床2期

2026-08-22

·同花顺财经

天士力上半年创新管线持续兑现

2026年上半年，国内医药行业在控费政策、市场竞争交织下持续调整，但优质企业却更多关注长期发展，坚持研发创新力度不减。天士力最新公布的半年报显示，公司依托稳健经营底盘持续加码创新布局，坚定执行“创新中药与先进治疗药物”双轮驱动战略，一批在研项目接连抵达关键临床与注册节点，创新转化效能持续释放，创新管线迎来集中兑现期。　　研发效率快速提升　　公告称，公司聚焦心血管及代谢、神经\/精神、消化三大核心领域，拥有在研创新药33项，其中处于NDA\/Pre NDA阶段3项，处于临床II、III期阶段18项。　　报告期内，公司以提升研发效率和创新能力为核心举措，稳步推进各项创新工作。在研发效率提升方面，公司聚焦创新中药与先进治疗药物两大板块，加速重磅产品上市进程。在创新中药领域，公司通过推进“现代中药创制全国重点实验室”建设，加快创新中药研发进程，报告期内1.1类中药创新药枣仁宁心滴丸获批上市，TCM2219申报NDA，TCM0117完成Pre NDA沟通交流会议，共18项创新中药处于临床II、III期及NDA阶段；在先进治疗药物领域，公司积极布局细胞与基因治疗(CGT)、小核酸等先进治疗药物赛道，3项CGT药物I期临床研究入组中，1项小核酸药物处于临床前研究。　　创新能力向“平台驱动”跃升　　在创新能力提升方面，公司以技术平台为底座，以高端人才为引擎，驱动研发能力从“经验驱动”向“平台驱动”跃升。在创新中药领域，重点攻关微滴丸制剂技术，已启动4项探索并突破2项共性技术；主导制定的中医药2项ISO国际标准正式发布，通过标准领先增强研发创新能力；在先进治疗药物领域，CGT赛道重点攻关“生物资源库、基因编辑平台与CMC开发平台”的“一库两平台”建设。报告期内，与北京市神经外科研究所等密切合作，联合申报获批“神经肿瘤细胞治疗北京市重点实验室”；在小核酸药物领域深化产学研合作，加速构建覆盖“序列设计-固相合成-先进递送”的全链条研发技术平台。为强化高端人才领航，公司持续优化研发人才结构，提升创新人才比例，重点引进CGT药物研发、小核酸药物研发、临床医学等前沿领域核心技术人才，不断夯实研发创新能力。　　临床申报高效推进　　公司提升研发效率，注册申报的关键里程碑高效达成。上半年公司创新药处于申报生产阶段项目4项，截至目前枣仁宁心滴丸获批上市，CMI1808申报生产已提交发补资料，TCM2219已提交NDA，TCM0117完成Pre NDA交流。此外，仿制药米诺地尔搽剂、波生坦分散片、富马酸伏诺拉生片获得药品注册批件，盐酸伐昔洛韦片通过一致性评价。上半年公司实现重要项目里程碑9项，除前述注册申报进展外，另有其他里程碑进展：TCM1802-01启动III期临床，CMI1203启动IIb期临床，BIO2601本年度新立项并已获批IND，CMI2402申报IND，TCM2105申报IND，TCM2601完成立项。对标年度计划，6项进度超前，包括TCM0013、TCM1207均提前完成III期全部病例入组，B2065I期临床已进入第三剂量组入组、TCM2008提前获得CDE的EOP2意见等。　　(

2026-08-22

·同花顺

天士力上半年创新管线持续兑现

2026年上半年，国内医药行业在控费政策、市场竞争交织下持续调整，但优质企业却更多关注长期发展，坚持研发创新力度不减。天士力（600535）最新公布的半年报显示，公司依托稳健经营底盘持续加码创新布局，坚定执行“创新中药与先进治疗药物”双轮驱动战略，一批在研项目接连抵达关键临床与注册节点，创新转化效能持续释放，创新管线迎来集中兑现期。研发效率快速提升公告称，公司聚焦心血管及代谢、神经/精神、消化三大核心领域，拥有在研创新药（002173）33项，其中处于NDA/Pre NDA阶段3项，处于临床II、III期阶段18项。报告期内，公司以提升研发效率和创新能力为核心举措，稳步推进各项创新工作。在研发效率提升方面，公司聚焦创新中药与先进治疗药物两大板块，加速重磅产品上市进程。在创新中药领域，公司通过推进“现代中药创制全国重点实验室”建设，加快创新中药研发进程，报告期内1.1类中药创新药（002173）枣仁宁心滴丸获批上市，TCM2219申报NDA，TCM0117完成Pre NDA沟通交流会议，共18项创新中药处于临床II、III期及NDA阶段；在先进治疗药物领域，公司积极布局细胞与基因治疗(CGT)、小核酸等先进治疗药物赛道，3项CGT药物I期临床研究入组中，1项小核酸药物处于临床前研究。创新能力向“平台驱动”跃升在创新能力提升方面，公司以技术平台为底座，以高端人才为引擎，驱动研发能力从“经验驱动”向“平台驱动”跃升。在创新中药领域，重点攻关微滴丸制剂技术，已启动4项探索并突破2项共性技术；主导制定的中医药2项ISO国际标准正式发布，通过标准领先增强研发创新能力；在先进治疗药物领域，CGT赛道重点攻关“生物资源库、基因编辑平台与CMC开发平台”的“一库两平台”建设。报告期内，与北京市神经外科研究所等密切合作，联合申报获批“神经肿瘤细胞治疗北京市重点实验室”；在小核酸药物领域深化产学研合作，加速构建覆盖“序列设计-固相合成-先进递送”的全链条研发技术平台。为强化高端人才领航，公司持续优化研发人才结构，提升创新人才比例，重点引进CGT药物研发、小核酸药物研发、临床医学等前沿领域核心技术人才，不断夯实研发创新能力。临床申报高效推进公司提升研发效率，注册申报的关键里程碑高效达成。上半年公司创新药（002173）处于申报生产阶段项目4项，截至目前枣仁宁心滴丸获批上市，CMI1808申报生产已提交发补资料，TCM2219已提交NDA，TCM0117完成Pre NDA交流。此外，仿制药米诺地尔搽剂、波生坦分散片、富马酸伏诺拉生片获得药品注册批件，盐酸伐昔洛韦片通过一致性评价。上半年公司实现重要项目里程碑9项，除前述注册申报进展外，另有其他里程碑进展：TCM1802-01启动III期临床，CMI1203启动IIb期临床，BIO2601本年度新立项并已获批IND，CMI2402申报IND，TCM2105申报IND，TCM2601完成立项。对标年度计划，6项进度超前，包括TCM0013、TCM1207均提前完成III期全部病例入组，B2065I期临床已进入第三剂量组入组、TCM2008提前获得CDE的EOP2意见等。(

临床3期核酸药物申请上市上市批准临床1期

100 项与富马酸伏诺拉生相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D10466	富马酸伏诺拉生	A02BC08	DB11739

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
非糜烂性胃食管反流病	美国	Phathom Pharmaceuticals, Inc.	2024-07-17
糜烂性食管炎	美国	Phathom Pharmaceuticals, Inc.	2023-11-01
胃灼热	美国	Phathom Pharmaceuticals, Inc.	2023-11-01
糜烂性胃食管反流病	韩国	Takeda Pharmaceuticals Korea Co., Ltd.	2019-03-29
十二指肠溃疡	日本	Takeda Pharmaceutical Co., Ltd.	2014-12-26
反流性食管炎	日本	Takeda Pharmaceutical Co., Ltd.	2014-12-26
幽门螺杆菌感染	日本	Takeda Pharmaceutical Co., Ltd.	2014-12-26
胃溃疡	日本	Takeda Pharmaceutical Co., Ltd.	2014-12-26

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
消化性溃疡出血	申请上市	中国	宜昌东阳光长江药业股份有限公司	2026-04-08
非糜烂性反流病	临床3期	美国	Phathom Pharmaceuticals, Inc.	2022-01-17
嗜酸粒细胞性食管炎	临床2期	美国	Phathom Pharmaceuticals, Inc.	2025-10-30
胃食管反流	临床2期	比利时	Takeda Pharmaceutical Co., Ltd.	2016-07-14
胃食管反流	临床2期	保加利亚	Takeda Pharmaceutical Co., Ltd.	2016-07-14
胃食管反流	临床2期	捷克	Takeda Pharmaceutical Co., Ltd.	2016-07-14
胃食管反流	临床2期	爱沙尼亚	Takeda Pharmaceutical Co., Ltd.	2016-07-14
胃食管反流	临床2期	波兰	Takeda Pharmaceutical Co., Ltd.	2016-07-14
胃食管反流	临床2期	英国	Takeda Pharmaceutical Co., Ltd.	2016-07-14
消化不良	临床1期	中国	浙江尖峰药业有限公司	2024-05-17

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


DDW2026	N/A	维生素B12缺乏症 \| 低镁血症 \| 骨折	7,069	Vonoprazan	淵壓鹽鹹壓簾獵鏇觸觸(鹹選蓋築齋築淵構鏇窪) = 餘願膚襯壓鏇繭糧鏇簾衊獵淵淵顧膚憲糧觸衊 (顧衊壓鹽衊願膚襯構遞 )	积极	2026-05-02
				PPIs (pantoprazole, omeprazole, rabeprazole, lansoprazole, esomeprazole)	淵壓鹽鹹壓簾獵鏇觸觸(鹹選蓋築齋築淵構鏇窪) = 網淵膚鏇遞鑰鏇製遞築衊獵淵淵顧膚憲糧觸衊 (顧衊壓鹽衊願膚襯構遞 )
DDW2026	N/A	幽门螺杆菌感染	77	vonoprazan	製鑰糧範構積願餘構鏇(鏇願餘醖築繭獵顧鹹積) = 壓簾鹹選糧範顧製鑰憲願範積獵築構顧鏇淵餘 (願鏇齋獵製餘製齋膚積 ) 更多	积极	2026-05-02
				tegoprazan	製鑰糧範構積願餘構鏇(鏇願餘醖築繭獵顧鹹積) = 獵製齋醖鏇範壓遞壓淵願範積獵築構顧鏇淵餘 (願鏇齋獵製餘製齋膚積 ) 更多
DDW2026	N/A	幽门螺杆菌感染二线	241	vonoprazan-amoxicillin dual therapy	遞構襯觸淵網糧遞廠窪(獵鏇齋積製鏇積遞膚製) = 夢繭顧製壓鏇憲糧構網鑰憲鹹醖網築遞觸襯醖 (繭遞壓積糧襯鑰衊蓋築 ) 更多	积极	2026-05-02
				vonoprazan-amoxicillin-minocycline-colloidal bismuth pectin quadruple therapy	遞構襯觸淵網糧遞廠窪(獵鏇齋積製鏇積遞膚製) = 構構鬱網築膚壓鹹築鹹鑰憲鹹醖網築遞觸襯醖 (繭遞壓積糧襯鑰衊蓋築 ) 更多
ChiCTR2300069857 (DDW2026)	临床4期	胃食管反流	540	Vonoprazan 20 mg once daily in the morning	鏇鏇鹽遞鹽遞膚窪範鬱(簾憲製艱襯觸壓範窪繭) = 構遞糧繭壓膚艱觸築願淵構衊獵簾網夢獵鹹鏇 (範廠觸廠簾夢範繭觸顧 )	不佳	2026-05-02
				Vonoprazan 20 mg once daily in the evening	鏇鏇鹽遞鹽遞膚窪範鬱(簾憲製艱襯觸壓範窪繭) = 夢築鏇願鏇鏇繭願糧艱淵構衊獵簾網夢獵鹹鏇 (範廠觸廠簾夢範繭觸顧 )
DDW2026	N/A	幽门螺杆菌感染	416	Vonoprazan 20 mg q.d. + Bismuth 220 mg b.i.d. + Amoxicillin 1000 mg b.i.d. + Clarithromycin 250 mg b.i.d.	艱廠艱簾齋獵膚遞鑰蓋(窪獵鹽遞築願糧壓憲襯) = 獵積鬱顧憲蓋夢餘製餘夢夢鏇鏇鹽鬱鏇範遞鏇 (獵鹹齋糧鑰廠窪齋築糧 ) 更多	积极	2026-05-02
				Esomeprazole 20 mg b.i.d. + Bismuth 220 mg b.i.d. + Amoxicillin 1000 mg b.i.d. + Clarithromycin 250 mg b.i.d.	艱廠艱簾齋獵膚遞鑰蓋(窪獵鹽遞築願糧壓憲襯) = 淵製壓齋顧簾繭網繭觸夢夢鏇鏇鹽鬱鏇範遞鏇 (獵鹹齋糧鑰廠窪齋築糧 ) 更多
DDW2026	N/A	胃肠道疾病	11,268	Vonoprazan	築鏇繭鏇鹽繭遞醖醖願(鹹蓋糧衊鹽網製餘顧餘) = 餘鹹築製廠壓餘壓夢壓顧遞製餘鹽餘襯艱獵鹽 (鹹鏇淵窪範蓋夢鏇遞顧 ) 更多	积极	2026-05-02
				Proton pump inhibitors (PPIs)	築鏇繭鏇鹽繭遞醖醖願(鹹蓋糧衊鹽網製餘顧餘) = 遞鹹齋糧觸獵觸製積製顧遞製餘鹽餘襯艱獵鹽 (鹹鏇淵窪範蓋夢鏇遞顧 ) 更多
DDW2026	临床1期	-	15	vonoprazan 20 mg once-daily	淵蓋窪繭遞選壓壓淵鑰(構廠網蓋齋淵壓蓋齋膚) = 簾鑰積蓋醖壓夢膚網壓範簾顧醖選選鏇夢餘簾 (鑰淵齋襯壓鏇遞積觸糧 )	积极	2026-05-02
				vonoprazan 20 mg twice-daily	淵蓋窪繭遞選壓壓淵鑰(構廠網蓋齋淵壓蓋齋膚) = 繭網窪餘鏇鹽壓繭齋獵範簾顧醖選選鏇夢餘簾 (鑰淵齋襯壓鏇遞積觸糧 )
DDW2026	N/A	幽门螺杆菌感染一线	1,577	PPI-clarithromycin-amoxicillin	膚夢餘簾廠窪淵壓遞遞(衊餘鏇膚壓鹹選壓範廠) = 餘壓窪糧築鬱顧窪簾膚鏇鏇築襯繭衊夢醖顧網 (簾構範夢窪齋齋糧艱齋 ) 更多	积极	2026-05-02
				vonoprazan-clarithromycin-amoxicillin	獵積襯餘範鬱廠糧窪蓋(選壓蓋鏇糧襯憲網鑰選) = 選壓鏇鹽蓋選膚襯鏇網餘膚夢糧獵範願衊鏇襯 (鬱範夢鹹齋夢鹽窪築壓 )
NCT06156085 (Pubmed \| J Formos Med Assoc)	临床4期	幽门螺杆菌感染一线	337	vonoprazan+amoxicillin	遞鏇構範醖遞憲簾壓鏇(鏇餘鏇壓衊窪鬱構顧鬱) = 衊艱構鬱醖繭鹹淵艱製糧衊獵選醖獵觸鑰鏇鹽 (膚夢夢齋製範夢鏇遞膚 ) 更多	非劣	2026-05-01
				lansoprazole+amoxicillin+clarithromycin+metronidazole	遞鏇構範醖遞憲簾壓鏇(鏇餘鏇壓衊窪鬱構顧鬱) = 築願願觸餘餘壓網艱齋糧衊獵選醖獵觸鑰鏇鹽 (膚夢夢齋製範夢鏇遞膚 ) 更多
NCT05191888 (Pubmed \| Am J Gastroenterol)	临床3期	幽门螺杆菌感染一线	906	Vonoprazan high-dose dual therapy	網鹹襯蓋選遞構鑰選簾(築觸壓淵糧製構觸顧糧) = 醖範網蓋觸築齋膚蓋築選膚鏇獵憲鬱衊鹽衊鹽 (憲觸鏇廠遞艱壓膚構壓 ) 更多	积极	2026-05-01
				Vonoprazan triple therapy	網鹹襯蓋選遞構鑰選簾(築觸壓淵糧製構觸顧糧) = 齋醖鏇窪襯襯齋夢簾網選膚鏇獵憲鬱衊鹽衊鹽 (憲觸鏇廠遞艱壓膚構壓 ) 更多